trending Market Intelligence /marketintelligence/en/news-insights/trending/2SQZ2B8OlkgGkg4STbQ1Rg2 content esgSubNav
In This List

Abzena out-licenses antibody technology

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Abzena out-licenses antibody technology

Abzena PLC licensed its ThioBridge technology that links antibodies and other proteins to drugs.

The agreement, with an undisclosed biopharmaceutical company in California, covers the use of the technology for up to 10 antibody drug conjugates for a wide range of indications.

The agreement could net up to $300 million to Abzena in license fees and milestone payments. Abzena would also receive royalties on sales of products that incorporate the technology.